RESEARCH & PUBLICATIONS

Lin Wu

A publication record at a glance

80	4,006	28
ARTICLES	CITATIONS	h-INDEX

PUBLICATION ACTIVITY

Articles by publication year



MOST CITED IN THIS LIST

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial — 582

2018 JAMA Oncology

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II–IIIA (N1–N2) EGFR-Mutant NSCLC (Adjuvant/CTONG1104): A Randomised, Open-Label, Phase 3 Study — 500

2018 Lancet Oncology, The

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. — 337

2019 Journal of Thoracic Oncology

This publication list was generated automatically from the exaly database without manual editing. It reflects the database records available when the document was created.

For the latest record and an updated publication list, visit the author profile:

https://exaly.com/author/994891

Document version: 2026-11-16 (UTC) | Database snapshot: 2026-11-15

Ordered by publication year, newest first

2026

01 Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

29 citations

Journal of Clinical Oncology · 44, 54-65

https://exaly.com/article/207619187

02 First-Line Aumolertinib (EGFR Tyrosine Kinase Inhibitor) Plus Apatinib (VEGFR Inhibitor) Versus Aumolertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients: A Randomized, Multicenter, Phase II Trial

0 citations

Signal Transduction and Targeted Therapy · 11, 40

https://exaly.com/article/210015107

03 CACA Guidelines for Holistic Integrative Management of Older Adults With Cancer

2 citations

Holistic Integrative Oncology · 5, 9

https://exaly.com/article/210131262

04 Aumolertinib With Carboplatin–Pemetrexed Versus Aumolertinib for Nonsmall Cell Lung Cancer With EGFR and Concomitant Tumor Suppressor Genes (ACROSS2): An Open-Label, Multicenter, Randomized Phase 3 Study

8 citations

Ca-A Cancer Journal for Clinicians · 76, e70071

https://exaly.com/article/211385373

05 Gotistobart or Docetaxel in Metastatic Squamous Non-Small Cell Lung Cancer: Stage 1 of the Randomized Phase 3 PRESERVE-003 Trial

2 citations

Nature Medicine · 32, 2245-2253

https://exaly.com/article/211923333

06 Real-World Serplulimab Plus Chemotherapy for Extensive-Stage Small Cell Lung Cancer in China: An External Validation of ASTRUM-005 Trial

1 citations

BMC Medicine

https://exaly.com/article/216121305

07 Oral KRAS G12D Inhibitor GFH375 for Previously Treated Advanced Solid Tumors With KRASG12D Mutations: A Phase 1 Trial.

1 citations

Nature Medicine · 32, 3302-3312

https://exaly.com/article/218306575

2025

08 A Plain Language Summary of Results From the CHOICE-01 Trial of Toripalimab Plus Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

0 citations

Future Oncology · 21, 515-522

https://exaly.com/article/195294751

Ordered by publication year, newest first

2025 / continued

09 **Glecirasib in KRASG12C-Mutated Nonsmall-Cell Lung Cancer: A Phase 2b Trial**
Nature Medicine · 31, 1-7
https://exaly.com/article/196389577
44 citations

10 **A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Socazolimab or Placebo Combined With Carboplatin and Etoposide in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer**
Signal Transduction and Targeted Therapy · 10, 1-8
https://exaly.com/article/196600845
17 citations

11 **A B7H3-Targeting Antibody–Drug Conjugate in Advanced Solid Tumors: A Phase 1/1b Trial**
Nature Medicine · 31, 1949-1957
https://exaly.com/article/198785492
124 citations

12 **Efficacy and Safety of Dacomitinib in Treatment-Naïve Patients With Advanced NSCLC and Brain Metastasis: A Multicenter Cohort Study**
Oncologist
https://exaly.com/article/199778277
2 citations

13 **Potential Biomarkers of Primary Resistance to First- and Second-Generation EGFR-TKIs in Non-Small-Cell Lung Cancer: A Real-World Study**
Therapeutic Advances in Medical Oncology · 17, 17588359251336632
https://exaly.com/article/200459639
2 citations

14 **Harnessing Local and System Immune Profiling Delineating Differential Responders to First-Line Sintilimab (Anti-PD-1 Antibody) Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer: An Exploratory Biomarker Analysis of a Phase II Study**
Signal Transduction and Targeted Therapy · 10, 168
https://exaly.com/article/201167091
10 citations

15 **First-Line Serplulimab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: Updated Results and Biomarker Analysis From the ASTRUM-005 Randomized Clinical Trial**
Cancer Communications · 45, 990-1009
https://exaly.com/article/201419074
26 citations

16 **Immune Checkpoint Inhibitor-Based Therapy as the First-Line Treatment for Advanced Non-Small Cell Lung Cancer: Efficacy, Challenges, and Future Perspectives**
Thoracic Cancer · 16, e70113
https://exaly.com/article/202216014
9 citations

Ordered by publication year, newest first

2025 / continued

17 Expert Consensus on the Diagnosis and Treatment of Malignant Mesothelioma of the Tunica Vaginalis Testis — 3 citations

iMetaMed · 1, e70003

https://exaly.com/article/203835988

18 First-Line Sacituzumab Tirumotecan With Tagitanlimab in Advanced Non-Small-Cell Lung Cancer: A Phase 2 Trial — 25 citations

Nature Medicine · 31, 1-8

https://exaly.com/article/203974249

19 Efficacy and Safety of Glecirasib in Solid Tumors With KRAS G12C Mutation: A Pooled Analysis of Two Phase I/II Trials — 16 citations

Cancer Communications · 45, 1500-1512

https://exaly.com/article/205371424

20 PACIFIC-5: A Phase III Clinical Trial of Consolidation Durvalumab in Patients With Unresectable Stage III NSCLC and No Progression After Concurrent or Sequential Chemoradiotherapy — 18 citations

Journal of Hematology and Oncology · 18, 111

https://exaly.com/article/208030293

2024

21 A Phase Ib/II Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Plus Anlotinib as First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer — 46 citations

British Journal of Cancer · 130, 1-7

https://exaly.com/article/174000408

22 Camrelizumab Combined With Apatinib and Nanoparticle Albumin-Bound Paclitaxel in Lung Adenocarcinoma (CAPAP-Lung): A Single-Arm Phase II Study — 10 citations

EClinicalMedicine · 67, 102403

https://exaly.com/article/175029025

23 Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722 — 175 citations

Journal of Clinical Oncology · 42, 1252-1264

https://exaly.com/article/175503604

Ordered by publication year, newest first

2024 / continued

24 Long-Term Survival of a Patient With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (NSCLC) and Untreated Multiple Brain Metastases Treated With Zorifertinib: A Case Report

Thoracic Cancer · 15, 1325-1329

https://exaly.com/article/184945333

1 citations

25 Vebreltinib for Advanced Non–Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study

Journal of Clinical Oncology · 42, 3680-3691

https://exaly.com/article/188185560

48 citations

26 Sintilimab in Combination With Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony-Stimulating Factor in Metastatic Non-Small Cell Lung Cancer: The Multicenter SWORD Phase 2 Trial

Nature Communications · 15, 1-14

https://exaly.com/article/188620989

25 citations

27 Phase Ib/II Study on the Safety, Tolerability, and Preliminary Efficacy of Pegylated Irinotecan (JK1201I) as Second-Line Monotherapy for Patients With Small-Cell Lung Cancer

Cancer Medicine · 13, e70059

https://exaly.com/article/188934588

2 citations

28 Efficacy in Patients With EGFR-Positive Non-Small-Cell Lung Cancer Treated With Dacomitinib Who Had Skin Adverse Events: Post Hoc Analyses From ARCHER 1050

Future Oncology · 20, 2971-2982

https://exaly.com/article/193421275

5 citations

29 Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (CHOICE-01): Final OS and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial

Signal Transduction and Targeted Therapy · 9, 1-9

https://exaly.com/article/196053866

35 citations

2023

30 Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Journal of Clinical Oncology · 41, 651-663

https://exaly.com/article/155178029

183 citations

Ordered by publication year, newest first

2023 / continued

31 Rh-Endostatin Plus Camrelizumab and Chemotherapy in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Multicenter Retrospective Study

18 citations

Cancer Medicine · 12, 7724-7733

https://exaly.com/article/158079306

32 Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial

10 citations

JCO Precision Oncology · 7, e2200708

https://exaly.com/article/163850904

33 First-Line Immunotherapy for Advanced Non-Small Cell Lung Cancer: Current Progress and Future Prospects

12 citations

Cancer Biology and Medicine · 21, 1-8

https://exaly.com/article/174281188

2022

34 A Novel Third-Generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-Mutant Non–Small Cell Lung Cancer: A Multicenter Phase I/II Study

21 citations

Clinical Cancer Research · 28, 1127-1135

https://exaly.com/article/120738180

35 Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901)

13 citations

Oncologist · 27, e116-e125

https://exaly.com/article/125267400

36 Three-Year Follow-Up and Patient-Reported Outcomes From CheckMate 078: Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer

22 citations

Lung Cancer · 165, 71-81

https://exaly.com/article/125394711

37 Genomic Correlates of Programmed Cell Death Ligand 1 (PD-L1) Expression in Chinese Lung Adenocarcinoma Patients

13 citations

Cancer Cell International · 22, 1-9

https://exaly.com/article/134678465

38 An Evaluation of Aumolertinib for the Treatment of EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

22 citations

Expert Opinion on Pharmacotherapy · 23, 647-652

https://exaly.com/article/134786085

Ordered by publication year, newest first

2022 / continued

39 Clinical and Genomic Features of Chinese Lung Cancer Patients With Germline Mutations

36 citations

Nature Communications · 13, 1-12

https://exaly.com/article/134802617

40 Anlotinib for Patients With Small Cell Lung Cancer and Baseline Liver Metastases: A Post Hoc Analysis of the ALTER 1202 Trial

22 citations

Cancer Medicine · 11, 1081-1087

https://exaly.com/article/135557724

41 The Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy or Anti-Angiogenic Therapy as a Second-Line or Later Treatment Option for Advanced Non-Small Cell Lung Cancer: A Retrospective Comparative Cohort Study

14 citations

Translational Lung Cancer Research · 11, 2111-2124

https://exaly.com/article/155905126

42 Sintilimab Versus Docetaxel as Second-Line Treatment in Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer: An Open-Label, Randomized Controlled Phase 3 Trial (ORIENT-3)

59 citations

Cancer Communications · 42, 1314-1330

https://exaly.com/article/156508687

2021

43 Dacomitinib Induces Objective Responses in Metastatic Brain Lesions of Patients With EGFR-Mutant Non-Small-Cell Lung Cancer: A Brief Report

31 citations

Lung Cancer · 152, 66-70

https://exaly.com/article/77915259

44 Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.

258 citations

Journal of Clinical Oncology · 39, 713-722

https://exaly.com/article/77932683

45 Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: 2-Year Follow-Up From a Randomized, Open-Label, Phase 3 Study (CheckMate 078)

57 citations

Lung Cancer · 152, 7-14

https://exaly.com/article/77957567

Ordered by publication year, newest first

2021 / continued

46 Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers
Frontiers in Immunology · 11, 607416
https://exaly.com/article/78562850
3 citations

47 Prediction of Egfr Mutation Status in Lung Adenocarcinoma Using Multi-Source Feature Representations
Journal unavailable
https://exaly.com/article/80989258
7 citations

48 Efficacy, Safety, and Genetic Analysis of Furmonertinib (AST2818) in Patients With EGFR T790M Mutated Non-Small-Cell Lung Cancer: A Phase 2b, Multicentre, Single-Arm, Open-Label Study
Lancet Respiratory Medicine,the · 9, 829-839
https://exaly.com/article/81791573
105 citations

49 Icotinib Versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant Non-Small-Cell Lung Cancer (EVIDENCE): A Randomised, Open-Label, Phase 3 Trial
Lancet Respiratory Medicine,the · 9, 1021-1029
https://exaly.com/article/82018819
173 citations

50 Sintilimab, Stereotactic Body Radiotherapy and Granulocyte–Macrophage Colony Stimulating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-In Results of a Multicenter, Single-Arm, Phase II Trial
Radiation Oncology · 16, 1-9
https://exaly.com/article/82042327
23 citations

51 Next-Generation Sequencing Assisted Diagnosis of Cervical Metastasis in EGFR-Mutated Lung Adenocarcinoma: A Case Report
Thoracic Cancer · 12, 2622-2627
https://exaly.com/article/82077939
4 citations

52 Effectiveness of Anlotinib in Patients With Small-Cell Lung Cancer and Pleural Effusion: Subgroup Analysis From a Randomized, Multicenter, Phase II Study
Thoracic Cancer · 12, 3039-3045
https://exaly.com/article/82435947
9 citations

53 Genomic Signatures Define Three Subtypes of EGFR-Mutant Stage II–III Non-Small-Cell Lung Cancer With Distinct Adjuvant Therapy Outcomes
Nature Communications · 12, 1-11
https://exaly.com/article/120740054
74 citations

Ordered by publication year, newest first

2021 / continued

54 Case Report: Tissue Origin Identification for Cancer of Unknown Primary: Gene Expression Profiling Approach — 4 citations

Frontiers in Oncology · 11, 702887

https://exaly.com/article/123325902

2020

55 Disparity in Clinical Outcomes Between Pure and Combined Pulmonary Large-Cell Neuroendocrine Carcinoma: A Multi-Center Retrospective Study — 44 citations

Lung Cancer · 139, 118-123

https://exaly.com/article/75376103

56 Quality of Life With Adjuvant Gefitinib Versus Vinorelbine Plus Cisplatin in Patients With Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutant Non-Small-Cell Lung Cancer: Results From the ADJUVANT (CTONG1104) Study — 10 citations

Lung Cancer · 150, 164-171

https://exaly.com/article/75514290

57 Silencing of Long Non-Coding RNA SOX21-AS1 Inhibits Lung Adenocarcinoma Invasion and Migration by Impairing TSPAN8 via Transcription Factor GATA6 — 18 citations

International Journal of Biological Macromolecules · 164, 1294-1303

https://exaly.com/article/75587836

58 Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People's Republic of China — 16 citations

JTO Clinical and Research Reports · 1, 100053

https://exaly.com/article/75622951

59 Safety and Efficacy of Aprepitant as Mono and Combination Therapy for the Prevention of Emetogenic Chemotherapy-Induced Nausea and Vomiting: Post-Marketing Surveillance in China — 7 citations

Chinese Clinical Oncology · 9, 68

https://exaly.com/article/75783722

60 Circulating Tumor DNA Clearance Predicts Prognosis Across Treatment Regimen in a Large Real-World Longitudinally Monitored Advanced Non-Small Cell Lung Cancer Cohort — 93 citations

Translational Lung Cancer Research · 9, 269-279

https://exaly.com/article/76605088

61 Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation — 100 citations

Journal of Thoracic Oncology · 15, 1015-1026

https://exaly.com/article/76960823

Ordered by publication year, newest first

2020 / continued

62 Peripheral Blood Biomarkers Associated With Outcome in Non-Small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy

Frontiers in Oncology · 10, 522464

https://exaly.com/article/77078029

42 citations

63 Abstract CT127: A Phase I Study of cMET Inhibitor Bozitinib in Patients With Advanced NSCLC Harboring cMET Alterations

Cancer Research · 80, CT127-CT127

https://exaly.com/article/118267582

20 citations

2019

64 The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

Journal of Thoracic Oncology · 14, 503-512

https://exaly.com/article/72819344

63 citations

65 Irinotecan Plus S-1 Versus S-1 in Patients With Previously Treated Recurrent or Metastatic Esophageal Cancer (ESWN 01): A Prospective Randomized, Multicenter, Open-Labeled Phase 3 Trial

Cancer Communications · 39, 16

https://exaly.com/article/73637864

24 citations

66 Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.

Journal of Thoracic Oncology · 14, 867-875

https://exaly.com/article/73702392

337 citations

67 The Impact of Previous Therapy Strategy on the Efficiency of Anlotinib Hydrochloride as a Third-Line Treatment on Patients With Advanced Non-Small Cell Lung Cancer (NSCLC): A Subgroup Analysis of ALTER0303 Trial

Translational Lung Cancer Research · 8, 575-583

https://exaly.com/article/74183415

32 citations

68 Population Pharmacokinetics and Individualized Lobaplatin Regimen for the Treatment of Chinese Small Cell Lung Cancer in the Elderly

Medicine (United States) · 98, e14136

https://exaly.com/article/74336387

0 citations

Ordered by publication year, newest first

2018

69 Association of microRNA-423 rs6505162 CA Polymorphism With Susceptibility and Metastasis of Colorectal Carcinoma
17 citations
Medicine (United States) · 97, e9846
https://exaly.com/article/69093807

70 Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II–IIIA (N1–N2) EGFR-Mutant NSCLC (Adjuvant/CTONG1104): A Randomised, Open-Label, Phase 3 Study
500 citations
Lancet Oncology, The · 19, 139-148
https://exaly.com/article/69735749

71 Immunotherapy for Non-Small Cell Lung Cancers: Biomarkers for Predicting Responses and Strategies to Overcome Resistance
48 citations
BMC Cancer · 18, 1-10
https://exaly.com/article/70369216

72 Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes Responding to Afatinib in Chinese Lung Cancer Patients
33 citations
OncoTargets and Therapy · 11, 7323-7331
https://exaly.com/article/70385859

73 Patient-Derived Tumor Immune Microenvironments in Patient-Derived Xenografts of Lung Cancer
14 citations
Journal of Translational Medicine · 16, 1-12
https://exaly.com/article/70400265

74 Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial
582 citations
JAMA Oncology · 4, 1569-1575
https://exaly.com/article/71670779

75 A Consensus on Immunotherapy From the 2017 Chinese Lung Cancer Summit Expert Panel
9 citations
Translational Lung Cancer Research · 7, 428-436
https://exaly.com/article/87912315

2017

76 Adenocarcinoma of the Lung With EGFR Gene Mutation and Subsequent Resistance Mechanisms Exploration: Case Report
1 citations
OncoTargets and Therapy · 10, 4517-4525
https://exaly.com/article/68449950

Ordered by publication year, newest first

2016

77 **miR-96 Induces Cisplatin Chemoresistance in Non-Small Cell Lung Cancer Cells by Downregulating SAMD9**

61 citations

Oncology Letters · 11, 945-952

https://exaly.com/article/64022752

78 **Effect of Transporter and DNA Repair Gene Polymorphisms to Lung Cancer Chemotherapy Toxicity**

18 citations

Tumor Biology · 37, 2275-2284

https://exaly.com/article/65767280

2015

79 **Mefunidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction**

28 citations

PLoS ONE · 10, e0129283

https://exaly.com/article/61044196

2014

80 **Fluorofenidone Offers Improved Renoprotection at Early Interventions During the Course of Diabetic Nephropathy in Db/Db Mice via Multiple Pathways**

10 citations

PLoS ONE · 9, e111242

https://exaly.com/article/57411421

End of list · 80 articles. Citation counts use Exaly’s peer-reviewed cohort.